Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleNEUROPHARMACOLOGY

Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the δ-Opioid Receptor Correlates with, but Does Not Require, G Protein Activation

Paulette A. Zaki, Duane E. Keith Jr., James B. Thomas, F. I. Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics September 2001, 298 (3) 1015-1020;
Paulette A. Zaki
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Duane E. Keith Jr.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
James B. Thomas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
F. I. Carroll
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher J. Evans
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In this study, we explored the relationship between ligand-induced regulation of surface δ opioid receptors and G protein activation. G protein activation was assessed with [35S]guanosine-5′-O-(3-thio)triphosphate (GTPγS) binding assays conducted at both 37 and 0°C. Ligand-independent (constitutive) activity of the δ-receptor was readily observed when the [35S]GTPγS binding assay was performed at 37°C. We identified a new class of alkaloid inverse agonists (RTI-5989-1, RTI-5989-23, RTI-5989-25), which are more potent than the previously described peptide inverse agonist ICI-174864 (N,N-diallyl-Tyr-Aib-Aib-Phe-Leu). Treatment with these inverse agonists for 18 h caused up-regulation of surface receptors. Eighteen-hour treatment with etorphine resulted in approximately 90% loss of surface receptor, whereas fentanyl, diprenorphine, and morphine caused between 20 and 50% loss. The abilities of ligands to modulate [35S]GTPγS binding at 37°C showed a strong correlation with their abilities to regulate surface receptor number (r2 = 0.86). Interestingly, the ability of fentanyl to activate G proteins was markedly temperature sensitive. Fentanyl showed no stimulation of [35S]GTPγS binding at 0°C but was as efficacious as etorphine, morphine, and diprenorphine at 37°C. Neither the ligand-induced receptor increases nor decreases were perturbed by pertussis toxin pretreatment, suggesting that functional G proteins are not required for ligand-regulated δ-opioid receptor trafficking.

Footnotes

  • This work was supported by National Institute on Drug Abuse Grants DA-05010 and DA-090454. P.A.Z. is a Hatos scholar and recipient of a predoctoral fellowship from the Howard Hughes Medical Institute.

  • Abbreviations:
    GPCR
    G protein-coupled receptor
    HEK
    human embryonic kidney
    GTPγS
    guanosine-5′-O-(3-thio)triphosphate
    ICI-174864
    N,N-diallyl-Tyr-Aib-Aib-Phe-Leu
    DOR
    δ-opioid receptor
    FITC
    fluorescein isothiocyanate
    BSA
    bovine serum albumin
    PTX
    pertussis toxin
    TIPP
    Tyr-Tic-Phe-Phe
    • Received May 18, 2001.
    • Accepted January 19, 2001.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 298 (3)
Journal of Pharmacology and Experimental Therapeutics
Vol. 298, Issue 3
1 Sep 2001
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the δ-Opioid Receptor Correlates with, but Does Not Require, G Protein Activation
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleNEUROPHARMACOLOGY

Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the δ-Opioid Receptor Correlates with, but Does Not Require, G Protein Activation

Paulette A. Zaki, Duane E. Keith, James B. Thomas, F. I. Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics September 1, 2001, 298 (3) 1015-1020;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleNEUROPHARMACOLOGY

Agonist-, Antagonist-, and Inverse Agonist-Regulated Trafficking of the δ-Opioid Receptor Correlates with, but Does Not Require, G Protein Activation

Paulette A. Zaki, Duane E. Keith, James B. Thomas, F. I. Carroll and Christopher J. Evans
Journal of Pharmacology and Experimental Therapeutics September 1, 2001, 298 (3) 1015-1020;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Experimental Procedures
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Iclepertin (BI 425809) in schizophrenia-related models
  • D1 agonist vs. methylphenidate on PFC working memory
  • Obesity Thwarts Preconditioning in TBI
Show more Neuropharmacology

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics